Multiple Myeloma: Targeted Therapy and Immunotherapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (31 August 2021) | Viewed by 43029
Special Issue Editor
Interests: hemopoietic stem cell; transplantation; autologous; allogeneic; haploidentical; graft versus tumor; graft versus host; consolidation therapy; maintenance therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
A cure for multiple myeloma, the second most common hematologic malignancy, remains elusive. Dysregulation of the immune system is a hallmark of this disease both at onset and during progression. Immune therapy — initially in the form of maintenance interferon therapy — has been around for at least four decades. Nevertheless, a highly effective therapy— at least in part — through the rectification of the compromised immune component of the bone marrow niche has gained general acceptance in the form of proteasome inhibitors, immune-modulatory agents (IMIDs), and more recently, monoclonal antibodies.
The further development of immune-based therapies has recently increased the clinical options for relapsed and/or refractory myeloma, which not only include “bare” monoclonal antibodies (alone or in combination), but also promising antibody–drug conjugates, bispecific antibodies, and bispecific T-cell engagers. Furthermore, chimeric antigen T-cell therapy is fast gaining approval in the treatment of multiple myeloma. Inhibition of the immune checkpoint blockade in relapsed myeloma has been hindered by unexpected toxicity. If the toxic side effect problem can be solved, the substantial antimyeloma activity seen in early trials may also provide breakthroughs. It is also expected that these novel therapeutics — in the field of newly diagnosed disease — will lead to further improvements in clinical results and eventually to a cure in a substantial number of patients.
This Special Issue will highlight one of the most rapidly developing fields of hematological cancer therapy, which may also serve as a model for other areas. Basic and clinical aspects will be covered to increase our understanding of targeted and immunotherapy in myeloma to facilitate progress from the bench to the bedside.
Dr. Gabor Mikala
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
